
Figure S5 The observed and expected PT values (a), and the covariate-only and PT-adjusted estimates for $AUC_{_{D-24}}$ (b), $C_{_{max}}$ (c), and $C_{_{trough}}$ (d) in the phase 3 EINSTEIN-DVT study. In panel a, the valid PT data are from the 20 mg o.d. dosing period of the phase 3 trial. Values for two individual patients, for whom PT adjustment led to a notable increase (purple) or decrease (orange) in exposure, are also shown as examples.



AUC₀₋₂₄, area under the plasma concentration-time curve from 0 to 24 h; C_{max}, maximum concentration; C_{trough}, trough concentration at the end of the dosing interval before the next dose; DVT, deep vein thrombosis; o.d., once a day; PK, pharmacokinetic; PT, prothrombin time; VTE-T, venous thromboembolism treatment.